Redfern Strategic Medical Communications

obesity

  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity
  • Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.

Navigation

  • Home
  • About RSMC
  • Services
  • Professional Highlights
  • What Colleagues Say
  • Browse the Examples
  • Contact

Featured Articles

  • Optimal pharmacotherapy to combat the atherogenic lipid triad.

    Optimal pharmacotherapy to combat the atherogenic lipid triad.

  • Prescription for publication. How to submit patient or physician attitudinal survey data to medical journals.

    Prescription for publication. How to submit patient or physician attitudinal survey data to medical journals.

  • Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce residual cardiovascular risk.

    Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce residual cardiovascular risk.

  • The risks and hazards of interpreting and reporting health study measures. A simple, practical overview.

    The risks and hazards of interpreting and reporting health study measures. A simple, practical overview.

  • Renal effects of COX-2 inhibitors.

    Renal effects of COX-2 inhibitors.

  • Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey.

    Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey.

  • Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity

  • Healthy food and healthy choices: a new European profile approach.

    Healthy food and healthy choices: a new European profile approach.

  • Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.

    Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.

  • Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.

    Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.

  • Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin.

    Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin.

  • Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis.

    Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis.

  • Managing hypertension in cardiology practice according to risk profile.

    Managing hypertension in cardiology practice according to risk profile.

Categories

  • Featured Article
  • Coauthored Article
  • Redfern Facilitated
  • Journal Article
  • Journal Supplement
  • Newsletter
  • Presentations
  • Abstract

Top Tags – Start Exploring RSMC

ACE inhibitors aging AIDS angiotensin anti-inflammatory antifungal antihyperglycemic agents antiretroviral aspergillosis aspirin atherosclerosis cancer cannabinoid receptor carcinoid cardiovascular disease caspofungin celecoxib cervical cancer cholesterol COX-2 inhibitor diabetes diarrhea dietary fiber dipeptidyl peptidase-iv endocrine tumors ezetimibe fibrates fish oil gallstones gastric acid gastrin gastroduodenal gastroduodenal mucosa gastrointestinal glucose tolerance hair loss health policy histamine histone deacetylase HIV HPV hypertension immunization infectious disease intestine lymphoma myocardial infarction naproxen neurology niacin NSAID obesity octreotide pepsin pepsinogen peptides pharmacokinetics propranolol prostaglandins public health renal disease renal function rofecoxib secretin somatostatin statins statistics stroke survey surveys tumor ulcer uric acid vaccine Zollinger-Ellison

Translate this Page

Admin

  • Register
  • Log in
  • Entries RSS
  • Comments RSS
© 2013 Redfern Strategic Medical Communications